ArticleTissue engineering. Part B, Reviews2018
Tissue-Engineered Heart Valves: A Call for Mechanistic Studies.
Article in Tissue engineering. Part B, Reviews, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Hydrogels in Cardiac Surgery: Versatile Platforms for Tissue Repair, Adhesion Prevention, and Localized Therapeutics.Gels (Basel, Switzerland) · 2025Review
- Optimization of Enzymatic and Chemical Decellularization of Native Porcine Heart Valves for the Generation of Decellularized Xenografts.International journal of molecular sciences · 2024Article
- Partial heart transplantation: Growing heart valve implants for children.Artificial organs · 2024Review
- Polymeric Heart Valves Will Displace Mechanical and Tissue Heart Valves: A New Era for the Medical Devices.International journal of molecular sciences · 2023Review
- Natural Polymers in Heart Valve Tissue Engineering: Strategies, Advances and Challenges.Biomedicines · 2022Review
- Clinical Impact of Computational Heart Valve Models.Materials (Basel, Switzerland) · 2022Review
- Bioprosthetic Aortic Valve Degeneration: a Review from a Basic Science Perspective.Brazilian journal of cardiovascular surgery · 2022Review
- Tissue engineering: Relevance to neonatal congenital heart disease.Seminars in fetal & neonatal medicine · 2022Review
- The horizon of pediatric cardiac critical care.Frontiers in pediatrics · 2022Review
- Surgical techniques for aortic valve xenotransplantation.Journal of cardiothoracic surgery · 2021Article
- Biological Characterization of Human Autologous Pericardium Treated with the Ozaki Procedure for Aortic Valve Reconstruction.Journal of clinical medicine · 2021Article
- Fourier transform infrared spectroscopy coupled with machine learning classification for identification of oxidative damage in freeze-dried heart valves.Scientific reports · 2021Article
- Next-generation tissue-engineered heart valves with repair, remodelling and regeneration capacity.Nature reviews. Cardiology · 2021Review
- Cellular Viability of Partial Heart Transplant Grafts in Cold Storage.Frontiers in surgery · 2021Review
- Biology and Biomechanics of the Heart Valve Extracellular Matrix.Journal of cardiovascular development and disease · 2020Review
- Development of Tissue Engineered Heart Valves for Percutaneous Transcatheter Delivery in a Fetal Ovine Model.JACC. Basic to translational science · 2020Article
- New Insights into Valve Hemodynamics.Rambam Maimonides medical journal · 2020Review
- Characterization of Laminins in Healthy Human Aortic Valves and a Modified Decellularized Rat Scaffold.BioResearch open access · 2020Article
- Article
- Sheep-Specific Immunohistochemical Panel for the Evaluation of Regenerative and Inflammatory Processes in Tissue-Engineered Heart Valves.Frontiers in cardiovascular medicine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Heart valve disease carries a substantial risk of morbidity and mortality. Outcomes are significantly improved by valve replacement, but currently available mechanical and biological replacement valves are associated with complications of their own. Mechanical valves have a high rate of thromboembolism and require lifelong anticoagulation. Biological prosthetic valves have a much shorter lifespan, and they are prone to tearing and degradation. Both types of valves lack the capacity for growth, making them particularly problematic in pediatric patients. Tissue engineering has the potential to overcome these challenges by creating a neovalve composed of native tissue that is capable of growth and remodeling. The first tissue-engineered heart valve (TEHV) was created more than 20 years ago in an ovine model, and the technology has been advanced to clinical trials in the intervening decades. Some TEHVs have had clinical success, whereas others have failed, with structural degeneration resulting in patient deaths. The etiologies of these complications are poorly understood because much of the research in this field has been performed in large animals and humans, and, therefore, there are few studies of the mechanisms of neotissue formation. This review examines the need for a TEHV to treat pediatric patients with valve disease, the history of TEHVs, and a future that would benefit from extension of the reverse translational trend in this field to include small animal studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.